The CONTEXT Study: Real-World Impact of GIQuant Motility MRI on Clinical and Radiological Assessment of Small Bowel Crohn's Disease

Iyad Naim, A. Menys1, R. Munyal,C. Clarke, J. Barber, K. Patel, N. Patel, A. Ocholi, D. Khodabakhshi, S. Baillie, N. Onyeador, V. Jennings, S. Vuyyuru, G. Bhatnagar, T. Shepherd, S. Upponi, J. De la Revilla Negro, K. Sethi-Arora, A. Kuzhiyanjal, J. Limdi, A. Win, P. Ghodekar, A.M. Siddiqui, D. Tolan, H. Lambie, H. Fitzke, W. Weston, P. Harrow, J. Yeo, M. Hameed, & G.W Moran, S.A Taylor

Motilent, London, UK.
Nottingham University Hospitals NHS Trust , UK.
Frimley Park Hospital, UK.
University College London Hospitals, UK.
Northern Care Alliance NHS Foundation Trust, UK
St George's Hospital, UK
Addenbrooke's- University of Cambridge, UK
Leeds Teaching Hospitals NHS Trust, UK

Evidence of utility

GIQuant as an objective MRI-Motility biomarker of treatment response in small bowel Crohn's Disease

Baseline (before anti-TNF)

GIQuant = 169.7

8 weeks

GIQuant = 353.9

FDA cleared & CE Marked by Motilent, London, UK

Plumb et al 2015 APT, Bettul et al. 2022 APR, Menys 2018 Radiology, Cococcioni et al. 2021 ER, Mishka et al 2025 ER and 30+ others

Design & Methods

- 12 Gastroenterologists and 12 Radiologists across six UK sites.
- A total of 276 patients (552 scans) generated 253 gastroenterologist and 276 radiologist assessments.
- We looked at their interaction with the technology.

Having reviewed the GIQuant results:

- How would you describe your diagnostic confidence?
- how would you describe the overall status of this patient?

Having reviewed the Post contrast IV Gad:

- How would you describe your diagnostic confidence?
- how would you describe the overall status of this patient?

Design & Methods

Having reviewed the GIQuant results:

- How would you describe your diagnostic confidence?
- how would you describe the overall status of this patient?

Having reviewed the Post contrast IV Gad:

- How would you describe your diagnostic confidence?
- how would you describe the overall status of this patient?

Radiologist questions & the REDCap eCRF

1. Patient history

- Demographics
- Eligibility
-Clinical details
-MRE details

2. Overall assessment

Your initial overall & segmental assessment based on anatomical scans and subjective assessment of 'cine' images.

3. +GIQuant

Does GIQuant impact your diagnostic confidence and disease status

DO NOT review any T1-weighted post-IV contrast imaging yet.

4. +IV Gad

Does IV Gad impact your overall & your diagnostic confidence and disease status

Gastroenterologists questions & the REDCap eCRF

1. Patient history

- Demographics
- Eligibility
-Clinical details

2. Conventional investigations

- Diagnosis
-Prognosis
- Surgical likelihood

3. GIQuant score reveal

- Hypothetically does GIQuant impact your assessment and treatment decisions ?

Results – Radiologists Diagnostic confidence

GIQuant

IV Gad

66%
GIQuant had some impact

22%
GIQuant having significant impact

43%
GIQuant increasing confidence

Results - Assessment of patient status

GIQuant

20%

Change in impression (52 of 222)

IV Gad

6%

Change in impression

Results - Gastroenterologists change in clinical impressions

In 47.4% of cases GIQuant influenced impression & flipped impression in 22% of cases.

Across clinical and radiological workflows, GIQuant provided additive, decision-changing information on CD activity. Motility MRI offers a valuable quantitative adjunct for tracking small bowel CD over time.

University of Nottingham
UK | CHINA | MALAYSIA

NHS
Frimley Health
NHS Foundation Trust

St George's Healthcare NHS
NHS Trust

NHS
The Leeds Teaching Hospitals
NHS Trust

NHS
Nottingham University Hospitals
NHS Trust

NHS
Northern Care Alliance
NHS Foundation Trust

NHS
Cambridge University Hospitals
NHS Foundation Trust

Motilent

NHS
University College London Hospitals
NHS Foundation Trust